Clinical

Dataset Information

Phase 2 study of DS-8201a in subjects with colorectal cancer [DESTINY-CRC01]


ABSTRACT: Intervention name : DS-8201a INN of the intervention : trastuzumab deruxtecan Dosage And administration of the intervention : IV solution (Once every 3 weeks, 6.4 mg/kg) Control intervention name : - INN of the control intervention : - Dosage And administration of the control intervention : - Primary outcome(s): efficacy The objective response rate RECIST Version 1.1 Study Design: multi center, open-label, 3-cohort study

DISEASE(S): Colorectal Cancer

PROVIDER: 2658293 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR